Petros Total Current Liabilities from 2010 to 2025
| PTPI Stock | USD 0.30 0.01 3.23% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 9.7 M | Current Value 9.2 M | Quarterly Volatility 13.3 M |
Check Petros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Petros Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 458.4 K, Income Tax Expense of 6.8 B or Tax Provision of 0.0, as well as many indicators such as Price To Sales Ratio of 0.45, Dividend Yield of 0.0 or PTB Ratio of 0.33. Petros financial statements analysis is a perfect complement when working with Petros Pharmaceuticals Valuation or Volatility modules.
Petros | Total Current Liabilities |
Latest Petros Pharmaceuticals' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Petros Pharmaceuticals over the last few years. Total Current Liabilities is an item on Petros Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Petros Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Petros Pharmaceuticals' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Petros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Petros Total Current Liabilities Regression Statistics
| Arithmetic Mean | 31,099,226 | |
| Geometric Mean | 26,732,591 | |
| Coefficient Of Variation | 42.68 | |
| Mean Deviation | 10,971,832 | |
| Median | 38,540,864 | |
| Standard Deviation | 13,274,471 | |
| Sample Variance | 176.2T | |
| Range | 34.8M | |
| R-Value | (0.76) | |
| Mean Square Error | 81.1T | |
| R-Squared | 0.57 | |
| Significance | 0.0007 | |
| Slope | (2,106,159) | |
| Total Sum of Squares | 2643.2T |
Petros Total Current Liabilities History
About Petros Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Petros Pharmaceuticals' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Petros Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 9.7 M | 9.2 M |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out the analysis of Petros Pharmaceuticals Correlation against competitors. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets | Return On Equity |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.